[A19-27] Fluticasone furoate/umeclidinium/vilanterol (COPD) - Addendum to Commission A18-79
Last updated 02.05.2019
Commission awarded on 26.03.2019 by the Federal Joint Committee (G-BA).
Airways and respiratory system
Maintenance treatment in adults with moderate to severe COPD who still have symptoms under a combination of a LABA and a LAMA
Additional analysis of a comparison with a treatment that is not in line with the appropriate comparator therapy; assessment result of A18-79 unchanged
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A18-79||Fluticasone furoate/umeclidinium/vilanterol (COPD) - Benefit assessment according to §35a Social Code Book V||Commission completed|
Federal Joint Committee (G-BA)
2019-05-02 A G-BA decision was published.